Diabetes News

Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.


Continuous glucose monitoring used with an insulin pump: should we recommend it to people with diabetes and can we afford it?

There is good evidence of the therapeutic benefit of continuous glucose monitoring, with a recent meta-analysis of randomized controlled trials using individual patient data confirming reductions in HbA1c with a reduction of hypoglycaemic episodes (Diabetic Medicine)

 

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics

This comprehensive review, which focuses on the European situation, summarises evidence for the efficacy and safety of CSII, particularly when used with RAIAs, in adult, paediatric, and pregnant populations, discusses relevant European guidelines, reviews issues that surround use of this technology, and discusses recent advances in pump technology, including the development of closed-loop ‘artificial pancreas’ systems (Diabetes/Metabolism Research and Reviews)

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles (Diabetes Care)

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? a long-term health economic analysis for the UK

Although associated with improved clinical outcomes, insulin intensification as practiced in the UK has a relatively high cost per QALY and may not lead to cost-effective outcomes for patients with type 2 diabetes as currently defined by UK cost-effectiveness thresholds (Diabetes Research and Clinical Practice)

American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015

These 2015 clinical practice guidelines (CPGs) for developing a diabetes mellitus (DM) comprehensive care plan are an update of the 2011 American Association of Clinical Endocrinologists (AACE) Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial

HGI calculated at baseline identified subpopulations in ACCORD with harms or benefits from intensive glycemic control. HbA1c is not a one-size-fits-all indicator of blood glucose control, and taking this into account when making management decisions could improve diabetes care (Diabetes Care)

FDA Advisory Panel Recommends Updated Labeling for Two DPP-4 Inhibitors

In two separate decisions, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that the labeling for saxagliptin (Onglyza, AstraZeneca) and alogliptin (Nesina, Takeda) be updated to include information on additional safety concerns that surfaced during cardiovascular (CV) outcomes trials (Endocrinology Advisor)

Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes

Mental health symptoms are associated with higher levels of patient-reported of diabetes-related symptoms, but the association between diabetes-related symptoms and subsequent regimen modifications is diminished in patients with greater depressive symptoms. Clinicians should focus attention on identifying and treating patients’ mental health concerns in order to address the role of diabetes-related symptom burden in guiding physician medication prescribing behaviour (Family Practice)